BiomX Receives NYSE American Non-Compliance Notice BiomX received an NYSE American non-compliance notice on Mar 27, 2026; the exchange’s $1.00 over 30 trading days price test is a key metric investors will watch closely.

BiomX Receives NYSE American Non-Compliance Notice: BiomX received an NYSE American non-compliance notice on Mar 27, 2026; the exchange’s $1.00 over 30 trading days price test is a key metric investors will watch closely. 👈 Read full analysis #BiomX #NYSE #NonCompliance #Investing #StockMarket

BiomX CEO Updates Shareholders on Company Transformation and Future Growth The CEO of BiomX shares strategic changes to strengthen the company, focusing on financial restructuring and pursuing new opportunities in advanced technologies.

BiomX CEO Updates Shareholders on Company Transformation and Future Growth #USA #Dover #BiomX #Michael_Oster #PHGE

BiomX Announces New Leadership to Propel Business Growth and Clinical Advancements BiomX has appointed Michael Oster as CEO and David Rokach as CFO to drive the company's growth and clinical strategy forward.

BiomX Announces New Leadership to Propel Business Growth and Clinical Advancements #United_States #Dover #BiomX #Michael_Oster #David_Rokach

BiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapy Investing.com -- BiomX (NYSE:PHGE) Inc. (NYSE American:PHGE) stock surged 60% after the clinical-stage company announced it has successfully initiated patient dosing in its Phase 2b trial evaluating BX004 for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections. The randomized, double-blind, placebo-controlled study will evaluate approximately 60 cystic fibrosis patients, with participants receiving either BX004 or placebo via inhalation twice daily for 8 weeks. The company expects topline results in the first quarter of 2026. "This first patient dosing marks a significant milestone for our BX004 program and for CF patients with chronic P. aeruginosa infections who desperately need new options," said Jonathan Solomon, Chief Executive Officer of BiomX. The trial follows encouraging Phase 1b/2a results where 14.3% of patients completely cleared infections after 10 days of treatment, including individuals who had been living with chronic infections for over a decade. BiomX’s phage therapy targets specific pathogenic bacteria that remain a leading cause of death in cystic fibrosis patients despite modern treatments. The company has already secured Fast Track and Orphan Drug designations from the FDA for BX004. The Phase 2b trial will measure multiple efficacy endpoints, including reduction in bacterial burden, improvements in lung function, and enhanced quality of life. BiomX anticipates feedback from the FDA in the second half of 2025 regarding plans to link bacterial reduction to clinical outcomes. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is PHGE one of them?

Click Subscribe #BiomX #CysticFibrosis #Phase2bTrial #StockMarket #Biotech